Dilaforette, focused on treatments for patients with sickle-cell disease, and Arabian Gulf University, based in Bahrain, have signed a Clinical Collaboration agreement for the Phase 2 proof of concept trial of sevuparin in patients with Sickle Cell Disease (SCD) experiencing acute Vaso-Occlusive CAlready a subscriber Login You have read all…